Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE TB
NCT07656012Phase 2Not yet recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2027
- Primary completion
- Feb 2031
- Countries
- 1
01
Overview
A Phase 2 trial of rifampicin in Tuberculosis (TB), sponsored by University of Wisconsin–Madison. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07656012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07656012.